Janssen was seeking to continue its collaboration with Fate Therapeutics with revised terms and conditions. However, FATE chose not to move forward with the partnership. As a result, collaboration activities will wind down in the first quarter of 2023.
Scott Wolchko, president and CEO of Fate Therapeutics, said the following about the news.
“We are disappointed that we were not able to align with Janssen on their proposal for continuation of our collaboration, where two product candidates targeting high-value, clinically-validated hematology antigens were set to enter clinical development in 2023.”
More Changes Coming to FATE
To go along with this, Fate Therapeutics is adjusting its business. That includes prioritizing clinical programs, as well as reducing operating expenses. This will have it laying off employees to ensure it has a three-year cash runway.
Fate Therapeutics ended the fourth quarter of 2022 with cash and cash equivalents of $475 million. The job cuts will also see it reduce its workforce to just 220 employees. This should provide it with enough funds to continue operations through 2025.
Heavy trading has FATE stock falling today as investors sell shares. As of this writing, some 15 million shares have been traded. For comparison, the company’s daily average trading volume is closer to 2.1 million shares.
FATE stock is down 62% as of Friday morning.
Investors looking for more recent stock market news are in luck!
InvestorPlace has all that news ready to go for Friday! A few examples include what has shares of Magic Empire (NASDAQ:MEGL), World Wrestling Entertainment (NYSE:WWE), and Chinese EV stocks moving today. You can get up to speed on all that news at the following links!
More Friday Stock Market News
- Dear MEGL Stock Fans, Mark Your Calendars for Jan. 31
- WWE Stock Gains 17% on Return of Former CEO
- Why Are Chinese EV Stocks NIO, XPEV, LI Down Today?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
More From InvestorPlace
- Buy This $5 Stock BEFORE This Apple Project Goes Live
- The Best $1 Investment You Can Make Today
- Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
- It doesn’t matter if you have $500 or $5 million. Do this now.
The post Why Is Fate Therapeutics (FATE) Stock Down 62% Today? appeared first on InvestorPlace.